Announced details
Hearing loss disorders, hearing loss treatments, and nonclinical research in preparation for clinical trials
Joint research has continued since June 2023. A certain level of progress and results has been achieved.
The parties have continued joint research on a hearing loss treatment since June 2023. The term of the joint research agreement will be extended.
A comprehensive life sciences university comprising Kitasato University, affiliated hospitals and research institutes, with 9 faculties and 18 departments. It is a school corporation founded by Kitasato Shibasaburo.
There is no change to the earnings forecast for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
WHO『Deafness and hearing loss』
| Item | Details |
|---|---|
| Names of Products / Services Covered | Hearing loss treatment |
| Counterparty | School Corporation Kitasato Institute |
| Counterparty overview | A comprehensive life sciences university comprising Kitasato University, affiliated hospitals and research institutes, with 9 faculties and 18 departments. It is a school corporation founded by Kitasato Shibasaburo. |
| Relationship with the Company | The parties have continued joint research on a hearing loss treatment since June 2023. The term of the joint research agreement will be extended. |
| Contract Date | 26 March 2026 (the Board of Directors resolved to extend the contract term) |
| Applicable area | Hearing loss disorders, hearing loss treatments, and nonclinical research in preparation for clinical trials |
| Usage history | Joint research has continued since June 2023. A certain level of progress and results has been achieved. |
| Impact on Business Performance | There is no change to the earnings forecast for the fiscal year ending December 2026. |
| Source | WHO『Deafness and hearing loss』 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To further obtain nonclinical data and evaluate efficacy using various assessment systems in preparation for the launch of future clinical trials, and to continue obtaining data and developing a research and development strategy for conducting company-sponsored clinical trials.